Changzhou National High-Tech Zone Holds Groundbreaking Ceremony: 70 New Production and Service Facilities to be Built This Year

Changzhou National High-Tech Zone notes construction is planned to start in 2021. The 70 projects represent a total investment of US$8.9 billion, of which, US$3.3 billion is expected to be made this year.

The projects include 47 manufacturing facilities with a total investment of US$4.6 billion, of which US$1.6 billion is earmarked for 2021. Emerging and specialized sectors account for more than 80% of what will be produced at the new facilities.

The projects are comprised of 17 at the municipal level, 51 at the district level and 2 categorized as key in supporting the transportation infrastructure. Sectors covered by the new projects include smart energy, new materials, electric vehicles, core auto parts, new medicines and medical devices, and next-generation information technology, as well as modern service sectors providing science and innovation platforms. The facilities are aimed at improving the ecological environment, enhancing industrial capacity and improving people’s livelihoods.

The event was held on the grounds where the Phase II project of Intersurgical Medical Device’s plant will be built. Officials from ten sub-districts gave short presentations on the number, value and structure of the investment projects in their respective jurisdictions.

Intersurgical Medical Device (Changzhou) Co., Ltd. is a wholly-owned subsidiary of Intersurgical, the largest manufacturer of respiratory and anesthesia medical devices in Europe. In 2014, the company invested in its Phase I project in the Life and Health Industrial Park of Changzhou National High-Tech Zone. The Phase II project has a total investment of UKP 36 million (approx. US$49 million), and a projected annual production capacity of 110 million units of medical equipment such as respiratory therapy devices, respiratory filtration devices and anesthesia masks, as well as 100 sets of trimming molds.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”